Advanced Malignant Cancer
6
2
2
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Clinical Trial of TQB3205 Capsule in Subjects With Advanced Malignant Tumors
A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsule in Subjects With Advanced Malignant Tumors
A Study of SHR-A1909 in Subjects With Advanced Malignant Tumors
Phase I Study of HRS-7053 Injection in the Treatment of Patients With Advanced Malignancies
A Clinical Trial of TQB3117 Tablets in Patients With Advanced Malignant Cancer
Phase I Study of SHR-2022 Injection in the Treatment of Patients With Advanced Malignant Tumors